Tag: liver diseases therapeutics market report

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Liver Diseases Therapeutics Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The realm of liver disease treatments has witnessed substantial expansion, anticipating a fiscal expansion from $15.18 billion in 2025 to $16.66 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.8%. This upward trajectory historically owes its momentum to the widespread incidence of viral hepatitis, a rise in alcohol-related liver ailments, the early adoption of antiviral and palliative remedies, a scarcity of effective interventions for enduring liver issues, and an increasing emphasis on hospital-centric liver management.

The therapeutics market for liver diseases is poised for significant expansion over the coming years, projected to reach a valuation of $24.27 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.9%. This anticipated growth trajectory is largely propelled by an escalating prevalence of metabolic liver conditions, a greater utilization of immunosuppressive and targeted treatment modalities, the development of an expanding array of liver cancer therapies in the pipeline, heightened public and professional understanding of the advantages of early disease intervention, and increased healthcare expenditure dedicated to managing chronic liver ailments. Key developments expected to shape this market during the forecast period encompass a heightened demand for antiviral treatments for hepatitis, a burgeoning emphasis on addressing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a continuous rise in the application of immunotherapy for liver cancer, the broader implementation of combination drug treatment regimens, and an increasing focus on comprehensive, long-term management strategies for liver diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

Liver Diseases Therapeutics Market Growth Drivers And Industry Catalysts

The increasing incidence of liver conditions is anticipated to be a significant driver for the expansion of the liver disease therapeutics market. Liver disease encompasses a broad spectrum of ailments that impact the liver’s function, and therapeutic interventions for these conditions aim to manage or cure them through diverse treatment modalities. Highlighting this trend, data from the UK’s Office for Health Improvement and Disparities revealed a concerning upward trajectory in mortality, with premature deaths attributed to alcoholic liver disease escalating by 3.6% in 2023 to reach 5,984, an increase from the 5,776 recorded the previous year. This escalating burden of liver-related ailments directly fuels the demand and subsequent growth within the liver disease therapeutics sector.

Liver Diseases Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

#Liver Diseases Therapeutics Market Trends Influencing Long-Term Demand

Within the liver disease therapeutics market, leading pharmaceutical and biotechnology firms are keenly investing in cutting-edge advancements, notably artificial intelligence, to empower medical professionals in the early detection of liver fibrosis. The integration of artificial intelligence into liver disease therapeutics involves leveraging sophisticated computational models and machine learning methodologies to scrutinize diverse medical datasets. This enables more prompt identification, accurate diagnosis, and tailored therapeutic approaches for individuals afflicted with liver conditions. As a practical illustration, in February 2023, Predictive Health Intelligence, a UK entity specializing in healthcare data management, unveiled hepatoSIGHT. This novel AI-driven instrument, hepatoSIGHT, possesses the capability to forecast the presence of liver fibrosis in patients diagnosed with chronic liver disease, serving as a valuable tool for case identification and patient cohort mapping to pinpoint those susceptible to chronic liver disease (CLD). Its design prioritizes security, user-friendliness, and efficiency, capable of processing vast quantities of data swiftly to isolate patients meeting predefined parameters. Furthermore, the system boasts robust data analytics, sophisticated machine learning algorithms, immediate risk assessment capabilities, and an accessible user interface.

Liver Diseases Therapeutics Market Key Companies And Competitive Benchmarking

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Access The Complete Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Diseases Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the liver diseases therapeutics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Liver Diseases Therapeutics Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The realm of liver disease treatments has witnessed substantial expansion, anticipating a fiscal expansion from $15.18 billion in 2025 to $16.66 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.8%. This upward trajectory historically owes its momentum to the widespread incidence of viral hepatitis, a rise in alcohol-related liver ailments, the early adoption of antiviral and palliative remedies, a scarcity of effective interventions for enduring liver issues, and an increasing emphasis on hospital-centric liver management.

The therapeutics market for liver diseases is poised for significant expansion over the coming years, projected to reach a valuation of $24.27 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.9%. This anticipated growth trajectory is largely propelled by an escalating prevalence of metabolic liver conditions, a greater utilization of immunosuppressive and targeted treatment modalities, the development of an expanding array of liver cancer therapies in the pipeline, heightened public and professional understanding of the advantages of early disease intervention, and increased healthcare expenditure dedicated to managing chronic liver ailments. Key developments expected to shape this market during the forecast period encompass a heightened demand for antiviral treatments for hepatitis, a burgeoning emphasis on addressing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a continuous rise in the application of immunotherapy for liver cancer, the broader implementation of combination drug treatment regimens, and an increasing focus on comprehensive, long-term management strategies for liver diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

Liver Diseases Therapeutics Market Growth Drivers And Industry Catalysts

The increasing incidence of liver conditions is anticipated to be a significant driver for the expansion of the liver disease therapeutics market. Liver disease encompasses a broad spectrum of ailments that impact the liver’s function, and therapeutic interventions for these conditions aim to manage or cure them through diverse treatment modalities. Highlighting this trend, data from the UK’s Office for Health Improvement and Disparities revealed a concerning upward trajectory in mortality, with premature deaths attributed to alcoholic liver disease escalating by 3.6% in 2023 to reach 5,984, an increase from the 5,776 recorded the previous year. This escalating burden of liver-related ailments directly fuels the demand and subsequent growth within the liver disease therapeutics sector.

Liver Diseases Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

#Liver Diseases Therapeutics Market Trends Influencing Long-Term Demand

Within the liver disease therapeutics market, leading pharmaceutical and biotechnology firms are keenly investing in cutting-edge advancements, notably artificial intelligence, to empower medical professionals in the early detection of liver fibrosis. The integration of artificial intelligence into liver disease therapeutics involves leveraging sophisticated computational models and machine learning methodologies to scrutinize diverse medical datasets. This enables more prompt identification, accurate diagnosis, and tailored therapeutic approaches for individuals afflicted with liver conditions. As a practical illustration, in February 2023, Predictive Health Intelligence, a UK entity specializing in healthcare data management, unveiled hepatoSIGHT. This novel AI-driven instrument, hepatoSIGHT, possesses the capability to forecast the presence of liver fibrosis in patients diagnosed with chronic liver disease, serving as a valuable tool for case identification and patient cohort mapping to pinpoint those susceptible to chronic liver disease (CLD). Its design prioritizes security, user-friendliness, and efficiency, capable of processing vast quantities of data swiftly to isolate patients meeting predefined parameters. Furthermore, the system boasts robust data analytics, sophisticated machine learning algorithms, immediate risk assessment capabilities, and an accessible user interface.

Liver Diseases Therapeutics Market Key Companies And Competitive Benchmarking

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Access The Complete Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Diseases Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the liver diseases therapeutics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Liver Diseases Therapeutics Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The realm of liver disease treatments has witnessed substantial expansion, anticipating a fiscal expansion from $15.18 billion in 2025 to $16.66 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.8%. This upward trajectory historically owes its momentum to the widespread incidence of viral hepatitis, a rise in alcohol-related liver ailments, the early adoption of antiviral and palliative remedies, a scarcity of effective interventions for enduring liver issues, and an increasing emphasis on hospital-centric liver management.

The therapeutics market for liver diseases is poised for significant expansion over the coming years, projected to reach a valuation of $24.27 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.9%. This anticipated growth trajectory is largely propelled by an escalating prevalence of metabolic liver conditions, a greater utilization of immunosuppressive and targeted treatment modalities, the development of an expanding array of liver cancer therapies in the pipeline, heightened public and professional understanding of the advantages of early disease intervention, and increased healthcare expenditure dedicated to managing chronic liver ailments. Key developments expected to shape this market during the forecast period encompass a heightened demand for antiviral treatments for hepatitis, a burgeoning emphasis on addressing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a continuous rise in the application of immunotherapy for liver cancer, the broader implementation of combination drug treatment regimens, and an increasing focus on comprehensive, long-term management strategies for liver diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

Liver Diseases Therapeutics Market Growth Drivers And Industry Catalysts

The increasing incidence of liver conditions is anticipated to be a significant driver for the expansion of the liver disease therapeutics market. Liver disease encompasses a broad spectrum of ailments that impact the liver’s function, and therapeutic interventions for these conditions aim to manage or cure them through diverse treatment modalities. Highlighting this trend, data from the UK’s Office for Health Improvement and Disparities revealed a concerning upward trajectory in mortality, with premature deaths attributed to alcoholic liver disease escalating by 3.6% in 2023 to reach 5,984, an increase from the 5,776 recorded the previous year. This escalating burden of liver-related ailments directly fuels the demand and subsequent growth within the liver disease therapeutics sector.

Liver Diseases Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

#Liver Diseases Therapeutics Market Trends Influencing Long-Term Demand

Within the liver disease therapeutics market, leading pharmaceutical and biotechnology firms are keenly investing in cutting-edge advancements, notably artificial intelligence, to empower medical professionals in the early detection of liver fibrosis. The integration of artificial intelligence into liver disease therapeutics involves leveraging sophisticated computational models and machine learning methodologies to scrutinize diverse medical datasets. This enables more prompt identification, accurate diagnosis, and tailored therapeutic approaches for individuals afflicted with liver conditions. As a practical illustration, in February 2023, Predictive Health Intelligence, a UK entity specializing in healthcare data management, unveiled hepatoSIGHT. This novel AI-driven instrument, hepatoSIGHT, possesses the capability to forecast the presence of liver fibrosis in patients diagnosed with chronic liver disease, serving as a valuable tool for case identification and patient cohort mapping to pinpoint those susceptible to chronic liver disease (CLD). Its design prioritizes security, user-friendliness, and efficiency, capable of processing vast quantities of data swiftly to isolate patients meeting predefined parameters. Furthermore, the system boasts robust data analytics, sophisticated machine learning algorithms, immediate risk assessment capabilities, and an accessible user interface.

Liver Diseases Therapeutics Market Key Companies And Competitive Benchmarking

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Access The Complete Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Diseases Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the liver diseases therapeutics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Liver Diseases Therapeutics Market During The 2026–2030 Period?

The liver diseases therapeutics market has demonstrated robust expansion in recent years. This sector is projected to increase from $15.18 billion in 2025 to $16.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. The historical growth can be attributed to the high prevalence of viral hepatitis infections, increasing alcohol-induced liver disease cases, early reliance on antiviral and supportive therapies, limited treatment options for chronic liver conditions, and growing hospital-based liver care.

The liver diseases therapeutics market size is projected for substantial expansion over the next few years. It is forecast to grow to $24.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.9%. This growth in the forecast period is primarily attributed to factors such as the increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, rising awareness of the benefits of early treatment, and increased healthcare spending on chronic liver diseases. Major trends expected during this period include a rising demand for antiviral therapies in hepatitis treatment, an increasing focus on NAFLD and NASH management, the growing adoption of immunotherapy in liver cancer, the expansion of combination drug therapies, and an enhanced emphasis on long-term disease management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Are The Main Drivers Accelerating The Growth Of The Liver Diseases Therapeutics Market?

The growing incidence of liver conditions is anticipated to fuel the expansion of the liver disease therapeutics market moving forward. Liver disease refers to any ailment affecting the liver. Liver disease therapeutics aid in managing liver conditions through various treatment methods. For example, in December 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, premature deaths due to alcoholic liver disease escalated by 3.6%, reaching 5,984, an increase from 5,776 in 2022. Thus, the increasing occurrence of liver diseases is a key driver for the growth of the liver disease therapeutics market.

Which Segment-Based Categories Are Covered In The Liver Diseases Therapeutics Market?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

Which Trends Are Guiding The Development Of The Liver Diseases Therapeutics Market?

Leading companies operating in the liver disease therapeutics market are concentrating on innovative technologies, such as artificial intelligence, to support clinicians in identifying patients with liver fibrosis early in their disease progression. Artificial intelligence in liver disease therapeutics involves utilizing advanced computational algorithms and machine learning techniques to analyze medical data, thereby assisting in early detection, diagnosis, and personalized treatment strategies for liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, introduced hepatoSIGHT. hepatoSIGHT is an innovative AI-powered tool capable of predicting liver fibrosis in patients with chronic liver disease, serving as a case-finding and cohort mapping utility designed to pinpoint individuals at risk of Chronic Liver Disease (CLD). It functions as a secure, intuitive, and easy-to-use system that can rapidly review millions of data points to identify patients who meet specified criteria. Moreover, its features include comprehensive data analysis, machine learning algorithms, real-time risk stratification, and a user-friendly interface.

Which Industry Players Are Present In The Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Access The Complete Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Which Area Represents The Largest Portion Of The Liver Diseases Therapeutics Market?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Liver Diseases Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Fatty Liver Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Liver Diseases Therapeutics Market In 2026, And How Will Its Value Evolve By 2030?

The market size for liver diseases therapeutics has experienced robust growth in recent years. It is anticipated to expand from $15.18 billion in 2025 to $16.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. The historical growth can be mainly ascribed to the high prevalence of viral hepatitis infections, a rise in alcohol-induced liver disease cases, an initial reliance on antiviral and supportive therapies, the limited treatment options for chronic liver conditions, and the expansion of hospital-based liver care.

The liver diseases therapeutics market is projected to undergo significant growth in the forthcoming years. It is forecast to expand to $24.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.9%. This expansion over the forecast period is primarily driven by an increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, greater awareness regarding the benefits of early treatment, and increased healthcare spending on chronic liver conditions. Prominent trends expected during this period include a heightened demand for antiviral treatments in hepatitis management, a stronger focus on NAFLD and NASH management, the increasing utilization of immunotherapy for liver cancer, the broader application of combination drug therapies, and a rising emphasis on long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Significant Factors Are Influencing The Liver Diseases Therapeutics Market Expansion?

The increasing incidence of liver diseases is projected to boost the expansion of the liver disease therapeutics market moving forward. Liver disease refers to any condition affecting the liver, and liver disease therapeutics are employed to manage these conditions through various treatments. For instance, in December 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, premature deaths due to alcoholic liver disease escalated by 3.6%, reaching 5,984, up from 5,776 in 2022. Thus, the rising prevalence of liver diseases is a key factor driving the growth of the liver disease therapeutics market.

Which Segments Define The Liver Diseases Therapeutics Market Segment Structure?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

What Trends Are Affecting The Direction Of The Liver Diseases Therapeutics Market?

Major companies in the liver disease therapeutics market are increasingly prioritizing innovative technologies, such as artificial intelligence, to empower clinicians in identifying patients with liver fibrosis at early stages of disease progression. The application of artificial intelligence in liver disease therapeutics entails employing advanced computational algorithms and machine learning techniques to meticulously analyze medical data, thereby assisting in the prompt detection, precise diagnosis, and personalized treatment strategies for various liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT. This innovative AI-powered tool is designed to predict liver fibrosis in patients afflicted with chronic liver disease. Serving as a case-finding and cohort mapping instrument, it aims to pinpoint individuals susceptible to chronic liver disease (CLD). It operates as a secure, intuitive, and user-friendly system, capable of scrutinizing millions of data lines within seconds to identify patients who satisfy predefined criteria. Moreover, its capabilities include comprehensive data analysis, sophisticated machine learning algorithms, real-time risk stratification, and an easily navigable interface.

Who Are The Established Players Within The Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Get The Full Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Which Region Accounts For The Largest Portion Of The Liver Diseases Therapeutics Market?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Liver Diseases Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Market Report

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Fatty Liver Treatment Market Report

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Liver Diseases Therapeutics Market In 2026, And How Will Its Value Evolve By 2030?

The market size for liver diseases therapeutics has experienced robust growth in recent years. It is anticipated to expand from $15.18 billion in 2025 to $16.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. The historical growth can be mainly ascribed to the high prevalence of viral hepatitis infections, a rise in alcohol-induced liver disease cases, an initial reliance on antiviral and supportive therapies, the limited treatment options for chronic liver conditions, and the expansion of hospital-based liver care.

The liver diseases therapeutics market is projected to undergo significant growth in the forthcoming years. It is forecast to expand to $24.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.9%. This expansion over the forecast period is primarily driven by an increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, greater awareness regarding the benefits of early treatment, and increased healthcare spending on chronic liver conditions. Prominent trends expected during this period include a heightened demand for antiviral treatments in hepatitis management, a stronger focus on NAFLD and NASH management, the increasing utilization of immunotherapy for liver cancer, the broader application of combination drug therapies, and a rising emphasis on long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Significant Factors Are Influencing The Liver Diseases Therapeutics Market Expansion?

The increasing incidence of liver diseases is projected to boost the expansion of the liver disease therapeutics market moving forward. Liver disease refers to any condition affecting the liver, and liver disease therapeutics are employed to manage these conditions through various treatments. For instance, in December 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, premature deaths due to alcoholic liver disease escalated by 3.6%, reaching 5,984, up from 5,776 in 2022. Thus, the rising prevalence of liver diseases is a key factor driving the growth of the liver disease therapeutics market.

Which Segments Define The Liver Diseases Therapeutics Market Segment Structure?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

What Trends Are Affecting The Direction Of The Liver Diseases Therapeutics Market?

Major companies in the liver disease therapeutics market are increasingly prioritizing innovative technologies, such as artificial intelligence, to empower clinicians in identifying patients with liver fibrosis at early stages of disease progression. The application of artificial intelligence in liver disease therapeutics entails employing advanced computational algorithms and machine learning techniques to meticulously analyze medical data, thereby assisting in the prompt detection, precise diagnosis, and personalized treatment strategies for various liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT. This innovative AI-powered tool is designed to predict liver fibrosis in patients afflicted with chronic liver disease. Serving as a case-finding and cohort mapping instrument, it aims to pinpoint individuals susceptible to chronic liver disease (CLD). It operates as a secure, intuitive, and user-friendly system, capable of scrutinizing millions of data lines within seconds to identify patients who satisfy predefined criteria. Moreover, its capabilities include comprehensive data analysis, sophisticated machine learning algorithms, real-time risk stratification, and an easily navigable interface.

Who Are The Established Players Within The Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Get The Full Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Which Region Accounts For The Largest Portion Of The Liver Diseases Therapeutics Market?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Liver Diseases Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Market Report

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Fatty Liver Treatment Market Report

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Liver Diseases Therapeutics Market By 2030 Starting From Its 2026 Size?

The liver diseases therapeutics market size has demonstrated strong growth in recent years. It is projected to increase from $15.18 billion in 2025 to $16.66 billion in 2026, at a compound annual growth rate (CAGR) of 9.8%. This historic period’s expansion can be ascribed to several factors, including the high prevalence of viral hepatitis infections, a rising number of alcohol-induced liver disease cases, an early reliance on antiviral and supportive therapies, the limited treatment options available for chronic liver conditions, and the expansion of hospital-based liver care.

The liver diseases therapeutics market size is anticipated to experience substantial growth in the upcoming years, expanding to $24.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This projected growth during the forecast period is primarily fueled by the increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, heightened awareness regarding the benefits of early treatment, and increased healthcare spending on chronic liver conditions. Significant trends in the forecast period include an escalating demand for antiviral therapies in hepatitis treatment, a concentrated focus on managing NAFLD and NASH, the increasing use of immunotherapy in liver cancer, the expansion of combination drug therapies, and a rising emphasis on long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Drivers Are Shaping The Future Growth Of The Liver Diseases Therapeutics Market?

The increasing occurrence of liver conditions is projected to drive expansion within the liver disease therapeutics market in the coming years. Liver disease encompasses any ailment impacting the liver, and liver disease therapeutics offer diverse treatments to address these conditions. For illustration, a December 2024 report from the Office for Health Improvement and Disparities, a UK government department, indicated a 3.6% rise in premature deaths from alcoholic liver disease in 2023, climbing to 5,984 from 5,776 in 2022. Consequently, the growing incidence of liver diseases is fueling the development of the liver disease therapeutics market.

Which Segment Categories Define The Liver Diseases Therapeutics Market?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

How Are Trends Transforming The Liver Diseases Therapeutics Market Landscape?

Leading companies within the liver disease therapeutics market are increasingly concentrating on advanced technologies, such as artificial intelligence, to assist clinicians in the early detection of liver fibrosis in patients during their disease progression. Artificial intelligence in liver disease therapeutics entails the utilization of sophisticated computational algorithms and machine learning techniques to analyze medical data, thereby aiding in prompt detection, accurate diagnosis, and customized treatment strategies for various liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT. This innovative AI-powered tool is designed to forecast liver fibrosis in individuals suffering from chronic liver disease. It functions as a case-finding and cohort mapping instrument, specifically developed to pinpoint patients at risk of chronic liver disease (CLD). The system is secure, intuitive, and straightforward to operate, possessing the ability to examine millions of data entries within seconds to identify patients meeting specific criteria. Additionally, its features encompass comprehensive data analysis, machine learning algorithms, real-time risk stratification, and a user-friendly interface.

Who Are The Top Companies Competing In The Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Read the full liver diseases therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Which Geographic Regions Are Influencing Demand In The Liver Diseases Therapeutics Market?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liver Diseases Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Global Market Report

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Fatty Liver Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model